Form 8-K - Current report:
SEC Accession No. 0001213900-24-108439
Filing Date
2024-12-12
Accepted
2024-12-12 17:05:10
Documents
14
Period of Report
2024-12-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0224646-8k_onconetix.htm   iXBRL 8-K 26684
2 PRESS RELEASE, DATED DECEMBER 12, 2024 ea022464601ex99-1_onconetix.htm EX-99.1 4195
  Complete submission text file 0001213900-24-108439.txt   208704

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20241206.xsd EX-101.SCH 3042
4 XBRL LABEL FILE onco-20241206_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE onco-20241206_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0224646-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 241545786
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)